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Tumour deposits are a significant prognostic factor in gastric cancer – a systematic review
and meta-analysis
Aims: Tumour deposits (TDs) are clusters of cancer
cells in the soft tissue that are discontinuous from the
primary tumour. In this review we are exploring their
relevance for prognosis in patients with gastric
cancer.
Methods and results: A literature search was per-
formed to identify studies providing data on TDs and
prognosis in gastric cancer patients. Eight papers were
included in the meta-analysis, which was carried out
in terms of risk ratios (RR) and hazard ratios (HR) with
95% confidence interval (95% CI). Of 7445 patients,
1551 had TDs (20.9%). TDs were associated with a
decreased overall survival (OS) in univariate
(HR = 2.82, 95% CI = 1.9–4.3) and multivariate
analyses (HR = 1.65, 95% CI = 1.3–2.1). TDs were
also associated with known prognostic factors such as
synchronous metastatic disease (RR = 9.5), invasion
depth (RR = 1.8), lymph node metastasis (RR = 1.7),
lymphatic invasion (RR = 1.7), vascular invasion
(RR = 2.6) and poor differentiation (RR = 1.2).
Conclusions: We found a strong indication that TDs
are independent predictors of prognosis in patients
with gastric cancer; hence, TDs should be included in
the staging of gastric cancers.
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Introduction
Gastric cancer (GC) is the fifth leading cause of can-
cer mortality worldwide, with a relatively high inci-
dence in eastern countries such as Japan, China or
Korea.1 Currently, the gold standard for GC treatment
in most parts of the world is surgery plus chemo(ra-
dio)therapy (CRT). This has been standard treatment
in Europe and North America for many years, respec-
tively,2,3 while postoperative chemotherapy is
standard in most Asian countries.4 A patient’s indi-
vidual treatment selection is based on disease stage,
as more advanced stages will require more aggressive
treatment, including chemotherapy and/or radiother-
apy. Staging is determined by the extent of invasion
of the primary tumour, the number of lymph node
metastases (LNM) and presence of distant metastases.
The current prognostic factors of GC are HER2 status,
residual disease (R0, R1, R2), the tumour site, age,
extent of resection and molecular subtype (TNM 8th
edition).5 In colorectal cancer (CRC), tumour deposits
(TDs) are included in staging because they have been
shown to be an independent prognostic factor.6–9
Until now, TDs have not been included in GC staging
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due to limited evidence, but are presumably also an
independent prognostic factor.10–16 TDs were first
described in 193517 in the rectum. Since then, ‘tu-
mour deposits’ have been reported under a variety of
other terms, such as ‘extranodal spread’,18 ‘positive
niduses in extranodal soft tissues’12 and ‘extranodal
metastases’.11,15 With regard to definition their origin
is controversial,10,13–15,18 as some authors consider
TDs to be metastatic lymph nodes that have lost their
structure, while others consider them to be dissemi-
nated cancer cells that originated from the primary
tumour. The consensus is that they are discrete
tumour foci found in surrounding fat (perigastric in
GC) that show no evidence of residual lymph node
tissue or continuity with the primary tumour.15
Therefore, we assessed the prognostic value of TDs
in GC patients by performing a systematic review of
published studies to determine whether the TD status
influences outcome in GC patients. On the basis of the
results, we will discuss whether TDs should be included
in future editions of the TNM staging guideline.
Methods
S E A R C H S T R A T E G Y A N D S E L E C T I O N C R I T E R I A
A comprehensive literature search was carried out
using the Pubmed and Web of Science search engines
from commencement to August 2018. The key words
used for this search were: ‘tumour deposits’, ‘extran-
odal metastasis’, ‘extranodal spread’ and ‘prognosis’ or
‘staging’ in combination with ‘gastric cancer’, ‘stom-
ach cancer’, ‘stomach tumour’ or ‘gastric tumour’.
Selection criteria included only original articles pub-
lished in English which included at least 50 patients
(Figure 1). In case of overlapping patient data, the
study with the largest number of patients was
included in this meta-analysis. Studies that included
patients with other primary tumours were excluded.
Lastly, studies in which histology was not reviewed
for the entire cohort were also excluded, as TD report-
ing was uncommon in past years and could be under-
reported in databases and pathology reports.
D A T A E X T R A C T I O N A N D S T A T I S T I C A L A N A L Y S I S
A meta-analysis was performed in terms of hazard ratio
(HR) or risk ratio (RR) with 95% confidence interval
(CI). The number of patients with and without TDs was
obtained from each study. The tumour–node–metasta-
sis (TNM) stage, HR, RR and overall survival (OS)
obtained from each study were also extracted and
entered in Review Manager version 5.3 (The Cochrane
Collaboration, Copenhagen: The Nordic Cochrane Cen-
tre, 2012). If HR data were not available in a certain
study, it was extracted from the Kaplan–Meier curves
using the Parmar estimation.19 The model used was a
random-effects model where weighting was performed
with the inverse variance. Heterogeneity was mea-
sured with I2, where a percentage higher than 50%
was considered a moderate heterogeneity of the sam-
ples. When heterogeneity was found, subanalysis was
performed. A logistic regression analysis was also per-
formed in order to investigate the multivariate relation-
ship of pathological risk factors.
Q U A L I T Y A S S E S S M E N T A N D R I S K O F B I A S
In order to assess the quality of the reporting in the
studies included, we followed the REMARK (REport-
ing recommendations for tumour MARKer prognostic
Articles (n = 896)
Excluded
Duplicates (n = 654)
Not in English (n = 3)
GC was not primary tumour (n = 196) 
No TD reporting (n = 25)
No original data (n = 2)
Excluded
Articles (n = 16)
Articles (n = 8)
< 50 patients (n = 1)
Extranodal extension (n = 4)
Gastroesophageal junction (n = 1)
Overlapping cohorts (n = 2)
Figure 1. Flowchart showing the article search strategy for the sys-
tematic review.The steps followed were identification of papers in
the search, selection with eligibility criteria and final inclusion of
papers. TDs, tumour deposits; CRT, chemoradiotherapy; RT, radio-
therapy; GC, gastric cancer.
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studies20) guidelines specifically focusing on TD
reporting (Supporting information, Table S1). Only
studies with data on outcome were included and
were therefore subjected to quality assessment. Scor-
ing was performed by two independent investigators
(C.G.M. and I.D.N.). In case of disagreement, a con-
sensus score was reached. All studies were scored
according to these recommendations as 1, reported
and 0, non-reported, and items that were not applica-
ble were excluded from the calculation. Nineteen cri-
teria were evaluated from all sections, giving special
attention to the Methods section.
Analysis of publication bias through visual inspec-
tion of symmetry of funnel plots (Supporting informa-
tion, Figure S1) was carried out. As the capacity to
detect this bias was limited by the small number of
studies included, the potential publication bias found
in the funnel plots should be treated with consider-
able caution.
E T H I C A L S T A N D A R D S
All procedures followed were in accordance with the
ethical standards of the responsible committee on
human experimentation at Radboudumc and with
the Helsinki Declaration of 1964 and later versions.
Results
S E A R C H R E S U L T S
A total of 896 papers were identified by searching
in Pubmed and Web of Science databases. Dupli-
cates and studies that did not meet the inclusion
criteria were excluded (Figure 1). Three studies had
overlapping patient data,12,21,22 thus we included
the study with the largest patient group.12 We
excluded studies with extranodal extension of lymph
node metastasis12,23–25 and a study with junction
cancers26 because it included patients with cancer
in the gastro-oesophageal junction. Lastly, one
study was excluded18 because of insufficient num-
ber of cases without capsule rupture. Finally, eight
studies were included for meta-analysis (Table 1),
comprising 8431 patients who did not have neoad-
juvant treatment.
Q U A L I T Y O F T H E R E P O R T I N G
Eight studies were included in the meta-analysis to cor-
relate TD presence with patient overall survival10–16,27
and with other prognostic factors such as lymph node
metastasis (LNM) and invasion depth. For lymph
vessel invasion (LVI) only five could be
included,11,13,14,16,27 and only four for vascular inva-
sion (VI).11,14,16,27 The median reporting of the stud-
ies calculated by a modified version of the REMARK
guideline table was 66.9%, ranging from 44.4% to
77.8% (Supporting information, Table S1).
P R O G N O S T I C I M P A C T O F T D S
Of the eight studies, the mean frequency of TDs was
20.9%, ranging from 10.6% to 36.7% (Table 1).
When TDs were present, overall survival was signifi-
cantly decreased in the univariate (HR = 2.82, 95%
CI = 1.87–4.28) and multivariate analysis
(HR = 1.65, 95% CI = 1.30–2.11) (Figure 2). Consid-
erable heterogeneity was observed between the stud-
ies (I2 = 96% in univariate and I2 = 41% in
multivariate analyses), which could be explained by
differences at the TNM stage. When studies were
grouped according to different proportion of T1–3
versus T4 patients, the heterogeneity disappeared
(I2 = 13%) (Supporting information, Figure S2). The
quality of reporting did not correlate with the magni-
tude of HR (Spearman’s r = 0.14; P = 0.75).
T D S A N D H I S T O L O G I C A L R I S K F A C T O R S
A S S O C I A T I O N
TDs occurred more frequently in tumours with a
higher T-category (T3/T4 versus T1/T2: RR = 1.82,
95% CI = 1.39–2.37) and T4 versus T1/T2/T3;
RR = 2.24, 95% CI = 1.62–3.09), LNM (RR = 1.71,
95% CI = 1.37–2.14), LVI (RR = 1.70, 95%
CI = 1.29–2.24), VI (RR = 2.64, 95% CI = 1.21–
5.74) and presence of metastases (RR = 9.50, 95%
CI = 2.79–32.33) (Figure 3). Heterogeneity was
found to be high (93–99%) among all comparisons.
When studies were grouped according to different
proportions of T1–3/T4 patients in each study, I2
(heterogeneity) was 0% for the T-category; it
decreased substantially for LVI (from 94% to 49%)
and reduced slightly for LNM and VI. Therefore, sub-
grouping by T category only explained invasion depth
and LVI heterogeneity. The other pathological risk
factor comparisons could not be explained by this
subgrouping or by sample size or study populations.
In spite of the high heterogeneity, the direction of the
effect in the forest plots was broadly consistent.
When analysing the histological grade of the
tumour, we found that poorly differentiated tumours
(high-grade tumours) had a higher risk of presenting
with TDs (RR = 1.23, 95% CI = 1.10–1.38) (Sup-
porting information, Figure S3A). High heterogeneity
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 809–816.
Tumour deposits in gastric cancer 811
could again be partially explained by T category
(when corrected, I2 decreased from 79% to 51%).
Analysis of histological Lauren subtypes28 gave
diverse individual study results in TD subtype preva-
lence. No specific subtype was found to have a higher
prevalence in our meta-analysis (RR = 1.05, 95%
Table 1. Overview of the characteristics of the included studies
Study Origin of cohorts Period time Tumour categories Number of patients % TDs
Anup et al.10 Fuzhou (China) Jan 2005–Dec 2010 I–IV 1250 (264)* 10.6
Ersen et al.27 Izmir (Turkey) Jan 1999–Dec 2010 I–IV 96 24.0
Etoh et al.11 Tokyo (Japan) Jan 1993–Dec 1996 I–IV 1023 14.3
Guo et al.12 Tianjin (China) Mar 2003–Dec 2011 I–IV 961 36.7
Lee et al.14 Seoul (South Korea) Jan 2004–Dec 2004 I–IV 653 23.9
Sun et al.13 Shenyang (China) Jan 1980–Mar 2010 I–IV 2998 17.8
Wang et al.15 Guangzhou (China) Jan 1994–Dec 2006 I–IV 1343 13.3
Yildiz et al.16 Eskisehir (Turkey) 2010–2015 I–IV 107 26.2
All studies 7445 20.9
*The incidence of TDs was determined using 1250 patients, but the rest of the calculations are based on 264 patients (case–cohort design,
matched for tumour category).
Study or subgroup log[HR] SE TD+ TD– Hazard Ratio IV, Weight Random 95% Cl 
Guo (2017) 0.3075 0.0639 534 2465
608
13.4% 1.36 [1.20 – 1.54]
Anup (2017) 0.392 0.1514 353 12.7% 1.48 [1.10 – 1.99]
Ersen (2014) 0.5878 0.2513 132 1118 11.4% 1.80 [1.10 – 2.95]
Sun (2012) 0.7178 0.0635 28 79 13.4% 2.05 [1.81– 2.32]
Wang (2011) 0.8595 0.0981 145 877 13.2% 2.36 [1.95 – 2.86]
Yildiz (2016) 1.0578 0.2342 156 397 11.6% 2.88 [1.82 – 4.56]
Etoh (2006) 1.9315 0.1852 23 12.3% 6.90 [4.80 – 9.92]
2.5572 0.1894 179 1164
73
12.2% 12.90 [8.90 – 18.70]
Total 
Heterogeneity:  Chi 2 = 187.47, df = 7 (P < 0.00001); I2 = 96% 
Lee(2013) 
1550 6781 100% 2.82 [1.87 – 4.28]
0.01 0.1 1 10 100
Test for Overall effect: Z = 4.91 (P < 0.00001) Favours TD + Favours TD –
Study or subgroup
Wang (2011) 0.345 0.1043
0.2
0.2134
179
146
156
481
1164 50.5% 1.41 [1.15 – 1.73]
1.82 [1.23 – 2.69]
2.09 [1.37 – 3.17]
25.8%
23.6%
100%
0.01 0.1
Favours TD + Favours TD –
1 10 100
1.65 [1.30 – 2.11]
777
497
2438
0.5988
0.7367
Etoh (2006)
Lee (2013)
Total
Heterogeneity: Chi 2 = 3.37, df = 2 (P = 0.19); I2 = 41%
Test for overall effect: Z = 4.06 (P < 0.0001)
log[HR] SE TD+   TD– Weight Hazard Ratio IV, Random 95% Cl
A
B
Figure 2. The impact of TDs on patient outcome, measured by overall survival with a univariate analysis (A) and multivariate analysis (B).
SE, standard error; TDs, tumour deposits; CI, confidence interval; IV, inverse variance.
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Study or subgroup
Ersen (2014) 15 23 43
489
879
56
1518
115
162
73 11.9% 1.11 [0.78 – 1.58]
1.19 [1.14 – 1.24]
1.29 [1.24 – 1.35]
1.36 [1.16 – 1.59]
1.40 [1.34 – 1.46]
4.16 [3.53 – 4.89]
4.71 [4.04 – 5.49]
1.82 [1.39 – 2.37]
15.0%
15.0%
14.3%
15.0%
14.3%
14.4%
100%
0.01 0.1
More TDs with
T1/T2 cases
More TDs with
T3/T4 cases
1 10 100
591
1164
79
2464
497
877
5745
353
179
28
534
156
146
1419
347
175
27
460
150
127
Guo (2017)
Wang (2011)
Yildiz (2016)
Sun (2012)
Lee (2013)
Etoh (2006)
Total
TD+ TD–
Weight Risk Ratio M-H, Random 95% ClEvents EventsTotal Total
Heterogeneity: Chi2 = 625.26, df = 6 (P < 0.00001); I2 = 99%
Test for overall effect: Z = 4.41 (P < 0.0001)
Study or subgroup
TD+ TD–
Weight Risk Ratio M-H, Random 95% ClEvents EventsTotal Total
Ersen (2014)
Guo (2017)
Etoh (2006)
Wang (2011)
Yildiz (2016)
Sun (2012)
Lee (2013)
9
54
108
Total 1551 5894
23 34
59
24
209
496
330
85
40
73 9.8%
12.9%
13.4%
14.0%
14.1%
13.3%
12.5%
100%
10.0%
132
79
1164
2464
877
608
497
0.01 0.1 1 10 100
132
28
179
534
146
353
156
143
137
255
75
12
Anup (2017)
0.84 [0.48 – 1.48]
2.90 [2.29 – 3.66]
8.60 [6.28 – 11.79]
2.18 [1.60 – 2.98]
2.49 [2.27 – 2.74]
2.37 [2.11 – 2.67]
2.33 [1.89 – 2.88]
1.41 [0.82 – 2.43]
0.92 [0.69 – 1.21]
Heterogeneity: Chi2 = 129.07, df = 7 (P < 0.00001); I2 = 95%
Test for overall effect: Z = 4.89 (P < 0.0001) More TDs 
when no LNM
More TDs when 
LNM
Study or subgroup
TD+ TD–
Weight Risk Ratio M-H, Random 95% ClEvents EventsTotal Total
0.01 0.1 1 10 100
Heterogeneity: Chi2 = 68.22, df = 4 (P < 0.00001); I2 = 94%
Test for overall effect: Z = 3.80 (P = 0.0001) More TDs when no LVI
More TDs when 
LVI
Ersen (2014)
Etoh (2006)
Yildiz (2016)
Sun (2012)
Lee (2013)
Total
136
225
22 28
19
887 3990
20.7%
100%
21.4%
18.4%
18.6%
21.0%
23
534
156 156
50
49 73
79
2464
877
497
685
382146131
1.70 [1.29 – 2.24]
2.78 [2.41 – 3.21]
1.24 [0.96 – 1.60]
1.23 [0.96 – 1.58]
1.52 [1.35 – 1.71]
2.06 [1.88 – 2.26]
Study or subgroup
TD+ TD–
Weight Risk Ratio M-H, Random 95% ClEvents EventsTotal Total
Ersen (2014)
Etoh (2006)
Yildiz (2016)
Lee (2013)
Total
0.01 0.1 1 10 100
More TDs 
when no VI
More TDs when 
VI
Heterogeneity: Chi 2 = 42.46, df = 3 (P < 0.00001); I2 = 93%
Test for overall effect: Z = 2.45 (P = 0.01)
94
156
146
62
23
203
73
79 23.0%
27.2%
25.1%
100%
24.6%
877
497
1526
20
21
353
28 288
13
2.64 [1.21 – 5.74]
9.41 [5.93 – 14.91]
2.78 [2.35 – 3.30]
0.81 [0.42 – 1.55]
2.06 [1.23 – 3.46]
A
B
C
D
E
Etoh (2006)
Lee (2013)
71 105
156
261
221
10
1941
497
2438
53.3% 5.94 [4.95 – 7.12]
16.25 [8.45 – 31.23]
9.50 [2.79 – 32.33]
0.01 0.1 1 10 100
46.7%
100%
51
Study or subgroup
TD+ TD–
Events EventsTotal
Total
Total Weight Risk Ratio M-H, Random 95% Cl
                   
Heterogeneity: Chi 2 = 13.09, df = 1 (P = 0.0003);  I2 = 92%
Test for overall effect: Z = 3.61 (P = 0.0003) More TDs when M0 More TDs when M1  
Figure 3. Association between TDs and histological risk factors. A, Correlation between TDs and higher tumour categories (T1/T2 versus
T3/T4). B, Correlation between TDs and LNM. C, Correlation between TDs and LVI. D, Correlation between TDs and VI. E, Correlation
between TDs and metastasis (M1). TDs: tumour deposits; LNM, lymph node metastasis; LVI, lymph vessel invasion; VI, vascular invasion;
M0, non-metastatic; M1, metastatic.
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CI = 0.77–1.44) (Supporting information, Figure S3B).
Heterogeneity could not be explained, although two
studies had consistent effects on the forest plot.
Discussion
In this systematic review and meta-analysis on TDs
in GC, eight studies were included, with a total of
7445 patients and a mean TD incidence of 20.9%.
Presence of TDs was associated with poor outcome in
univariate analysis (HR = 2.82). To understand more
clearly the importance of TDs as an independent
prognostic factor, a multivariate analysis was per-
formed on survival which showed a HR of 1.65, with
a 95% CI from 1.30 to 2.11 (Figure 2). These corre-
lations suggest that TDs are also an independent poor
prognostic factor, as in these studies the effect was
corrected for other risk factors such as invasion
depth, LNM, LVI and VI. Furthermore, TDs correlated
with known poor prognostic factors such as syn-
chronous metastatic disease (RR = 9.50), LNM
(RR = 1.71), LVI (RR = 1.70), VI (RR = 2.64) and
invasion depth (RR = 1.82–2.24). This evidence fur-
ther supports our contention that TDs could be an
informative trait when staging a patient’s disease pro-
gression, and therefore should also be included in GC
staging.
Most studies did not report Lauren’s histological
subtypes of tumours; therefore, we cannot draw con-
clusions on incidence of TDs in different subtypes.
Upon analysis of the studies that included the Lauren
classification, we did not observe any association
between subtype and TD prevalence. Poorly differenti-
ated tumours more often presented TDs (RR = 1.23),
which is consistent with previous literature29 where
it was stated that a higher histological grade (undif-
ferentiated tumours) are correlated with higher T cat-
egories, and therefore with worse prognosis.
Although TDs in CRC have been included in the
TNM classification since 1997, their prognostic value
in other cancers such as GC is still debated. Many
individual studies have reported TDs to be an inde-
pendent prognostic factor in GC but, to the best of
our knowledge, there is no meta-analysis to group
these findings and demonstrate their significance. A
recent study30 which included a review on the
impact of TDs in GC highlighted the undeniable prog-
nostic impact of TDs and the need to conform a strat-
egy for staging and treatment. Therefore, our results
can only be compared to those in which TDs have
been demonstrated to be an independent prognostic
factor, such as for CRC. A recent meta-analysis of
TDs in CRC included more than 10 000 patients31
with a mean TD prevalence of 22%, very similar to
our results, i.e. 21%. When the authors assessed the
relation between TDs and other risk factors they
found associations with presence of LNM, distant
metastasis and extramural vascular invasion. With
the available information from the studies we
included, we were able to establish associations with
TD presence and LNM, tumour invasion depth, LVI,
VI, histological grade and especially metastasis,
showing that TDs are certainly associated with poor
outcome.
As with all meta-analyses, the main drawback is
the publication bias, as studies that show negative or
insignificant results are less likely to be published.
Another limitation is that we identified a number of
papers in non-English language which could not be
used in the meta-analysis. A major disadvantage is
that only Asian papers are included, which poten-
tially indicate that it may not be applicable to the glo-
bal population. This is not surprising, as in western
countries locally advanced tumours (with proven
higher prevalence of TDs) are treated with neoadju-
vant therapy. However, we did not find any reports
including data from patients presenting TDs after
neoadjuvant CRT treatment. Conversely, as these are
patient groups that have not been treated with post-
operative CRT, we were able to establish the true
prognostic impact of TDs. Lastly, we believe that
there might be a risk of bias in reporting on the
prevalence of TDs. This could be due to the fact that
TDs may have been reported in older studies as
lymph node metastasis or vessel infiltration, and
could potentially mean that TDs might be even more
prevalent than estimated, which highlights the neces-
sity of TDs reporting.
The need to include TDs in gastric cancer staging
is indisputable, but the next step would be to discuss
where they should be included. Unfortunately, there
is no consensus with respect to the origin of TDs
and many hypotheses have been explored, especially
in CRC. In the first hypothesis, TDs are thought to
originate from extranodal extension of LNM,32,33
and would therefore be metastatic LNs that have
lost their LN characteristic shape and structures and
are, hence, mislabelled as TDs when in fact they are
LNs. In the second hypothesis, TDs are thought to
originate from (lympho)vascular invasion or perineu-
ral invasion, where cancer cells depart from the pri-
mary tumour and then disseminate into the
surrounding soft tissues.32 This might occur through
lymph vessels, blood vessels or nerves, as well as
through seeding in the fat tissue. As stated in a
study for TDs in rectal cancer, the aggressive
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 74, 809–816.
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characteristics of TDs and their success in dissemi-
nating through different pathways suggest they
could be a satellite focus for systemic dissemina-
tion.33 Thirdly, it is thought that they could be con-
tinuous to the primary tumour, and that this could
be seen when cutting deeper into the tissue, as
occurs with extramural invasion when cutting tan-
gentially.34 Lastly, in cases where patients have
been treated pre-operatively, TDs are thought to be
remnants of disease after therapy, and their signifi-
cance is still being discussed.35
With the information from the studies we included
and the correlation we observe with poor prognostic
factors, we are inclined to believe that the second
hypothesis might be the most factual hypothesis.
Some of the studies included10,13,15 even provided a
TNM adjustment for their cases, and found that
patients with TDs had similar survival curves to those
patients without TDs but with N3, M115 or T4 stag-
ing.10,13 Another study14 proposed they should be
included in the N-category not because of their ori-
gin, but because in their cohort, TD+ patient survival
behaved more like that of pN1 patients. A possibility
would be to include TD reporting separately, as is
done with LVI and VI, where a simple binary out-
come could be added. Having the recent experience of
including TDs in CRC we believe that it should not,
in any case, be included only when LNM is absent, as
TDs have been shown to provide additional informa-
tion in the presence of lymph node metastases.
In conclusion, this meta-analysis shows poor GC
prognosis when TDs are present. They are associated
with many other pathological risk factors and have
proved to be an independent prognostic factor,
although they are still not included in staging for GC.
Because of this, we propose that TDs be reported and,
as stated above, should be considered an independent
prognostic factor.
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